<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578317</url>
  </required_header>
  <id_info>
    <org_study_id>120103</org_study_id>
    <secondary_id>12-I-0103</secondary_id>
    <nct_id>NCT01578317</nct_id>
  </id_info>
  <brief_title>Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant</brief_title>
  <official_title>Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Adjuvants are substances included in vaccines that stimulate the immune system and increase
      the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in
      Europe. However, it has not been fully tested in the United States. Researchers want to test
      the immune responses of people who receive a bird flu vaccine with or without AS03 to better
      understand how the adjuvant works. This information may help develop better flu vaccines.

      Objectives:

      - To compare the healthy immune system responses to bird flu vaccine with or without the AS03
      adjuvant.

      Eligibility:

      - Healthy volunteers between 18 and 45 years of age.

      Design:

        -  Participants will be screened with a physical exam and medical history.

        -  Participants will be assigned to one of two groups. Each group will have an initial
           vaccine, followed by a booster vaccine 21 days later. Both vaccinations will use the
           same type of vaccine. One group will have the vaccine with AS03; the other group will
           have the vaccine without it.

        -  All participants will have two 36-hour inpatient stays to receive the vaccine. Each stay
           will involve the vaccination, followed by regular and frequent blood draws. Participants
           will be monitored for any signs or symptoms that may be caused by the vaccine.

        -  Additional blood samples will be collected 7, 28, 42, and 100 days after the initial
           vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvants have been in use for many decades to enhance the effects of vaccines on the host
      immune system, yet we know very little on how they actually work. Better understanding of the
      mechanism by which adjuvants activate the immune system will enable us to develop better and
      safer vaccines as well as a broad range of immune interventions to a wide spectrum of
      diseases including cancer and autoimmunity.

      In the current study we propose to study the effect of AS03 adjuvant on the innate/early
      immune response to H5N1, avian flu, a potentially lethal disease that most subjects are
      assumed to be naive to AS03 is an adjuvant oil in water emulsion containing
      DL-alpha-tocopherol, squalene and the non-ionic detergent Tween 80 that has been widely used
      as an adjuvant to flu vaccines produced by GlaxoSmithKline(GSK).

      We therefore propose to randomize up to 60 healthy volunteers into two intervention arms (25
      volunteers in each arm with up to 10 total replacements in the event a volunteer does not
      return for the first vaccine). The first arm will receive a vaccine containing H5N1 with AS03
      adjuvant, the second arm will receive H5N1 without AS03 adjuvant. Both arms will receive
      primary and booster vaccination followed by repeated blood sampling to evaluate the immune
      responses. We will apply high throughput analytic techniques and use systems biology methods
      to integrate the collected data and draw a description of the immune system response with and
      without the adjuvant.

      The primary objective is to compare multiplex immune response signatures following two
      (primary and a boost) vaccinations with the GSK AS03 adjuvanted H5N1 influenza vaccine, or
      the non-adjuvanted form of the H5N1 influenza vaccine, at the 3.75 mcg dose and given 21 days
      apart and identify differences in very early innate immune responses. These immune signatures
      will also be correlated with the clinical observations especially safety related local and
      systemic events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 20, 2012</start_date>
  <completion_date type="Actual">January 31, 2016</completion_date>
  <primary_completion_date type="Actual">January 31, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flu Antibody Titers</measure>
    <time_frame>Days 0, 21, 42, and 100</time_frame>
    <description>Flu Antibody titers at days 0, 21, 42, 100. Antibody-neutralization titers by microneutralization were measured against five different H5N1 virus strains (i.e., A/Vietnam/1194/2004 (clade 1), A/Indonesia/5/2005 (clade 2.1), A/Turkey/15/2006 (clade 2.2), A/Egypt/3072/2010 (clade 2.2), and A/Anhui/1/2005 (clade 2.3.4)) at day 0 (prevaccination), day 21 (post first vaccination), day 42 (post second vaccination) and day 100 postvaccination for AS03-adjuvanted group and unadjuvanted group. Sera were tested at an initial dilution of 1:20, and those that were negative (&lt;1:20) were assigned a titer of 10.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>AS03 adjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adminsitered day 1, booster at Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unadjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer day 1 and booster at Day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H5N1 vaccine plus AS03 adjuvant</intervention_name>
    <description>H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.</description>
    <arm_group_label>AS03 adjuvanted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H5N1 vaccine without adjuvant</intervention_name>
    <description>H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.</description>
    <arm_group_label>unadjuvanted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Healthy status confirmed by History, Physical Exam and blood work through the CHI
                  Screening Protocol.

               2. Age 21 years to 45 years

               3. Able to comprehend the investigational nature of the protocol and provide
                  informed consent

               4. Must be willing to use effective birth control for one month before, during and
                  for two months after the last vaccination.

        EXCLUSION CRITERIA:

          1. Severe allergies to eggs or their products, chicken proteins or to any component of
             the influenza antigen preparation.

          2. Recipient of AS03 vaccine at any time in the past

          3. Recipient of the seasonal influenza vaccine within the past 3 months.

          4. Prior severe reactions to vaccines, including influenza vaccines (e.g. anaphylaxis,
             angioedema or urticaria)

          5. Participation on any blood collection or blood donation procedure during study that
             will bring the total blood draw &gt;550ml over 8 weeks

          6. Current pregnancy (women of child bearing potential must have a negative serum
             pregnancy test done on screening within 1 week of protocol accrual)

          7. Currently breast-feeding

          8. History of Guillain Barre syndrome

          9. Acute illness with patient reported temperature of 38 (Infinite)C or greater within 3
             days prior to the proposed time of administration.

         10. Any history or presence of serious illness, bleeding disorders or autoimmune
             disorders, or planned surgeries.

         11. Weight less than 50 kg (110 pounds)

         12. History of hepatitis or liver disease.

         13. Subjects receiving immunosuppressive therapy.

         14. Presence of HLA DQB1*06:02, the narcolepsy risk associated allele.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John S Tsang, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-I-0103.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 1;43(9):1135-42. Epub 2006 Sep 25.</citation>
    <PMID>17029131</PMID>
  </reference>
  <reference>
    <citation>Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4(2):e4384. doi: 10.1371/journal.pone.0004384. Epub 2009 Feb 6. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/5f2ae0fb-53f1-48c2-aa19-9114765ba029. Capecchi, Pamela [corrected to Capecchi, Pier Leopoldo].</citation>
    <PMID>19197383</PMID>
  </reference>
  <reference>
    <citation>Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001 Mar 21;19(17-19):2673-80.</citation>
    <PMID>11257408</PMID>
  </reference>
  <results_reference>
    <citation>Khurana S, Coyle EM, Manischewitz J, King LR, Gao J, Germain RN, Schwartzberg PL, Tsang JS, Golding H; and the CHI Consortium. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ Vaccines. 2018 Oct 1;3:40. doi: 10.1038/s41541-018-0076-2. eCollection 2018.</citation>
    <PMID>30302282</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <results_first_submitted>February 22, 2019</results_first_submitted>
  <results_first_submitted_qc>February 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H5N1 Vaccine</keyword>
  <keyword>H5N1 Immunization</keyword>
  <keyword>AS03 Adjuvant</keyword>
  <keyword>Biologic Sample Collection</keyword>
  <keyword>Laboratory Research Specimens</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AS03 Adjuvanted</title>
          <description>Adminsitered day 1, booster at Day 21
H5N1 vaccine plus AS03 adjuvant: H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.</description>
        </group>
        <group group_id="P2">
          <title>Unadjuvanted</title>
          <description>Administer day 1 and booster at Day 21
H5N1 vaccine without adjuvant: H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analysis Population</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AS03 Adjuvanted</title>
          <description>Adminsitered day 1, booster at Day 21
H5N1 vaccine plus AS03 adjuvant: H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.</description>
        </group>
        <group group_id="B2">
          <title>Unadjuvanted</title>
          <description>Administer day 1 and booster at Day 21
H5N1 vaccine without adjuvant: H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.59" spread="6.64"/>
                    <measurement group_id="B2" value="30.85" spread="5.62"/>
                    <measurement group_id="B3" value="32.28" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>self reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Self reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Self reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flu Antibody Titers</title>
        <description>Flu Antibody titers at days 0, 21, 42, 100. Antibody-neutralization titers by microneutralization were measured against five different H5N1 virus strains (i.e., A/Vietnam/1194/2004 (clade 1), A/Indonesia/5/2005 (clade 2.1), A/Turkey/15/2006 (clade 2.2), A/Egypt/3072/2010 (clade 2.2), and A/Anhui/1/2005 (clade 2.3.4)) at day 0 (prevaccination), day 21 (post first vaccination), day 42 (post second vaccination) and day 100 postvaccination for AS03-adjuvanted group and unadjuvanted group. Sera were tested at an initial dilution of 1:20, and those that were negative (&lt;1:20) were assigned a titer of 10.</description>
        <time_frame>Days 0, 21, 42, and 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AS03 Adjuvanted</title>
            <description>Adminsitered day 1, booster at Day 21
H5N1 vaccine plus AS03 adjuvant: H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.</description>
          </group>
          <group group_id="O2">
            <title>Unadjuvanted</title>
            <description>Administer day 1 and booster at Day 21
H5N1 vaccine without adjuvant: H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Flu Antibody Titers</title>
          <description>Flu Antibody titers at days 0, 21, 42, 100. Antibody-neutralization titers by microneutralization were measured against five different H5N1 virus strains (i.e., A/Vietnam/1194/2004 (clade 1), A/Indonesia/5/2005 (clade 2.1), A/Turkey/15/2006 (clade 2.2), A/Egypt/3072/2010 (clade 2.2), and A/Anhui/1/2005 (clade 2.3.4)) at day 0 (prevaccination), day 21 (post first vaccination), day 42 (post second vaccination) and day 100 postvaccination for AS03-adjuvanted group and unadjuvanted group. Sera were tested at an initial dilution of 1:20, and those that were negative (&lt;1:20) were assigned a titer of 10.</description>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/5/05 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="6.4"/>
                    <measurement group_id="O2" value="10.35" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/5/05 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.09" spread="60.53"/>
                    <measurement group_id="O2" value="10.35" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/5/05 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600.92" spread="487.05"/>
                    <measurement group_id="O2" value="20" spread="74.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/5/05 Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.57" spread="133.05"/>
                    <measurement group_id="O2" value="18.59" spread="49.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Turkey/15/2006 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.32" spread="2.13"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Turkey/15/2006 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.99" spread="15.95"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Turkey/15/2006 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.65" spread="313.55"/>
                    <measurement group_id="O2" value="10.72" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Turkey/15/2006 Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.82" spread="20.12"/>
                    <measurement group_id="O2" value="11.16" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Egypt/3072/2010 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="6.4"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Egypt/3072/2010 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.59" spread="34.83"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Egypt/3072/2010 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.68" spread="291.7"/>
                    <measurement group_id="O2" value="11.89" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Egypt/3072/2010 Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="35.02"/>
                    <measurement group_id="O2" value="11.57" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Anhui/1/2005 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="6.4"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Anhui/1/2005 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" spread="16.77"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Anhui/1/2005 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.23" spread="173.42"/>
                    <measurement group_id="O2" value="10.72" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Anhui/1/2005 Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.95" spread="33.78"/>
                    <measurement group_id="O2" value="12" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1203/2004 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="6.4"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1203/2004 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.99" spread="14.92"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1203/2004 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="66.76"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1203/2004 Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.49" spread="15.69"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AS03 Adjuvanted</title>
          <description>Adminsitered day 1, booster at Day 21
H5N1 vaccine plus AS03 adjuvant: H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.</description>
        </group>
        <group group_id="E2">
          <title>Unadjuvanted</title>
          <description>Administer day 1 and booster at Day 21
H5N1 vaccine without adjuvant: H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Hemoglobin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decreased Neutrophils</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decreased White Blood Cells</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Increased White Blood Cells</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Increased Respiratory Rate</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Redness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain at Injection Site</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Tsang</name_or_title>
      <organization>NIH</organization>
      <phone>301-496-0304</phone>
      <email>tsangjs@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

